Human epidermal growth factor 2 positive (HER2+) breast cancer accounts for approximately 20% of breast malignancies, characterized by amplification of the HER2 gene and overexpression of its transmembrane tyrosine kinase receptor. This evidence concerns the gene ERBB2 and breast carcinoma.